NEW YORK, Sept. 10, 2010 (GLOBE NEWSWIRE) -- Regenicin, Inc. (OTCBB:WDST), a clinical-stage biotechnology company, announced today that it will hold a media and investor conference at the NASDAQ MarketSite on Tuesday, September 14, 2010 at 1:00 pm EDT. CEO Randy McCoy, senior executives and board members will be present.
The conference follows Regenicin's recent announcements appointing Amgen Co-founder Dr. Joseph Rubinfeld and Pfizer's Dr. Craig Eagle as independent members of their Board of Directors.
ATTEND IN PERSON:
When: September 14, 2010, 1:00 pm EDT
Where: NASDAQ MarketSite, 4 Times Square, New York, NY (43rd and Broadway)
RSVP required for building security: 212.691.2800 or strell@sunshinesachs.com
LIVE VIDEO WEBCAST
Please click here, September 14, 2010, 1:00 pm EDT
Mr. McCoy and his team will be available for interviews prior and post conference. Please contact Jay Strell, 212.691.2800 or strell@sunshinesachs.com
About Regenicin ™
Regenicin, Inc. is a development-stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. It is devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets with PermaDerm,™ which is the only tissue-engineered skin prepared from a patient's own skin cells. The company is headquartered in New York, NY.
CONTACT: Sunshine, Sachs & Associates Jay Strell 212.691.2800 strell@sunshinesachs.com